Selegiline Transdermal System
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Selegiline transdermal system (STS) has been approved to treat major depressive disorder in the USA. STS represents a novel…
basis), respectively. RESULTS For the majority of patients, STS was prescribed as a second or third treatment option for MDD…
OBJECTIVE
Selegiline transdermal system (STS) is efficacious for the treatment of major depressive disorder (MDD). This meta…
Selegiline transdermal system (STS) is a recently approved monoamine oxidase inhibitor antidepressant. This article reports…
Although older monoamine oxidase inhibitors (MAOIs) are effective in the treatment of depressive disorders, they are…
Effective antidepressant drugs have been available for half a century since the first monoamine oxidase inhibitor (MAOI…
The selegiline transdermal system (STS) is being developed to treat major depressive disorder. In a Phase I clinical study, the…
Two preclinical sensitization studies were conducted to determine the potential for allergic contact dermatitis with the…
Somerset is developing a selegiline transdermal system (STS) for potential use in the treatment of depression. It has also been…
The toxicology and toxicokinetics of a selegiline transdermal system (STS) were evaluated in a 3 month dog study of daily 24 h…